Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advaned gastric or gastroesophageal junction carcinoma

Annals of Oncology

Volumn 15, Issue 5, 2004, Pages 765-769

  Mitry, Emmanuel ^a   Taieb J ^b   Artru, P ^a   Boige, V ^b   Vaillant, J N ^a   Clavero Fabri, M C ^a   Ducreux, M ^b   Rougier, P ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antineoplastic combined chemotherapy; Cisplatin; Fluorouracil; Stomach neoplasms

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMACH CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 2642562231     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh182     Document Type: Article

References (18)

1. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
3. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
4. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
5. Kim NK, Park YS, Heo DS et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818.
6. Louver C, de Gramont A, Demuynck B et al. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann Oncol 1991; 2: 229-230.
7. Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648-2657.
8. Ajani J, Van Cutsem E, Moiseyenko V et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003; 22: 249 (Abstr 999).
9. Vanhoefer U, Wagner T, Lutz M et al. Randomized phase II study of weekly 24 h infusion of high dose 5-FU ± folinic acid (HD-FU ± FA) versus RD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC-trial 40953. Eur J Cancer 2001; 37 (Suppl 6): 27.
10. Villing AL, Thabut D, Ouldkaci M et al. Association CDDP-LV5FU2 dans les cancers gastriques, pancréatiques et cholangiocarcinomes avancés étude de faisabilité: résultats préliminaires (résumé). Bull Cancer 1998; 85: A426.
11. Taieb J, Lecomte T, Ezenfis J et al. 5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer. Gastroenterol Clin Biol 2002; 26: 605-609.
12. Taieb J, Mitry E, Boige V et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol 2002; 13: 1192-1196.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Star Assoc 1958; 53: 457-481.
15. Rougier P, Ducreux M, Mahjoubi M et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 9: 1263-1269.
16. Kim T, Choi S, Ahn J et al. A prospective randomized phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5-FU (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC). Eur J Cancer 2001; 37 (Suppl 6): 314.
17. Louver C, Carrat F, Mal F et al. Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Invest 2003; 21: 14-20.
18. Tournigand C, de Gramont A, Louvet C et al. A simplified bi-monthly regimen with leucovorin (LV) and 5-fluorouracil (5FU) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 1998; 17: 274a.